JAGSNPHARMNSEJagsonpal Pharmaceuticals Limited· PharmaceuticalsLowNeutral
Announced Thu, 24 Jul · 17:07 IST

Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Grant of ESOP'.

Capital Market Events View source PDF

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Jagsonpal Pharmaceuticals has informed stock exchanges that its Nomination and Remuneration Committee, at a meeting held on July 24, 2025, approved the grant of 2,72,500 employee stock options (ESOPs) under the company's Employees Stock Option Plan, 2022. Each option is exercisable at Rs. 216 per option and is convertible into one equity share of Rs. 2 face value. The options will vest in 4 equal annual tranches, starting from the first anniversary of the grant date. The intimation has been filed with both BSE (Scrip Code: 507789) and NSE (Symbol: JAGSNPHARM).

Likely market impact

This is a routine ESOP allotment and is likely to cause minor dilution for existing shareholders once options are exercised, but no immediate impact on share price is expected. Employees receiving the options at Rs. 216 may benefit if the stock trades above this level when options are exercised.